| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 10684 | 2021 |
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1331 | 2019 |
| Cabozantinib in progressive medullary thyroid cancer R Elisei, MJ Schlumberger, SP Müller, P Schöffski, MS Brose, MH Shah, ... Journal of clinical oncology 31 (29), 3639, 2013 | 1211 | 2013 |
| PI3Kγ is a molecular switch that controls immune suppression MM Kaneda, KS Messer, N Ralainirina, H Li, CJ Leem, S Gorjestani, ... Nature 539 (7629), 437-442, 2016 | 1010 | 2016 |
| Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck EEW Cohen, F Rosen, WM Stadler, W Recant, K Stenson, D Huo, ... Journal of clinical oncology 21 (10), 1980-1987, 2003 | 766 | 2003 |
| Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study EEW Cohen, LS Rosen, EE Vokes, MS Kies, AA Forastiere, FP Worden, ... Journal of Clinical Oncology 26 (29), 4708, 2008 | 741 | 2008 |
| Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas TY Seiwert, Z Zuo, MK Keck, A Khattri, CS Pedamallu, T Stricker, C Brown, ... Clinical cancer research 21 (3), 632-641, 2015 | 659 | 2015 |
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ... Journal of Clinical Oncology 29 (19), 2660, 2011 | 618 | 2011 |
| American Cancer Society head and neck cancer survivorship care guideline EEW Cohen, SJ LaMonte, NL Erb, KL Beckman, N Sadeghi, ... CA: a cancer journal for clinicians 66 (3), 203-239, 2016 | 595 | 2016 |
| Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer EEW Cohen, TG Karrison, M Kocherginsky, J Mueller, R Egan, CH Huang, ... Journal of clinical oncology 32 (25), 2735, 2014 | 552 | 2014 |
| The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) EEW Cohen, RB Bell, CB Bifulco, B Burtness, ML Gillison, KJ Harrington, ... Journal for immunotherapy of cancer 7, 1-31, 2019 | 532 | 2019 |
| Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum … JPH Machiels, RI Haddad, J Fayette, LF Licitra, M Tahara, JB Vermorken, ... The Lancet Oncology 16 (5), 583-594, 2015 | 460* | 2015 |
| Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck JSW Stewart, EEW Cohen, L Licitra, CML Van Herpen, C Khorprasert, ... Journal of clinical oncology 27 (11), 1864-1871, 2009 | 435 | 2009 |
| Characterization of HPV and host genome interactions in primary head and neck cancers M Parfenov, CS Pedamallu, N Gehlenborg, SS Freeman, L Danilova, ... Proceedings of the National Academy of Sciences 111 (43), 15544-15549, 2014 | 412 | 2014 |
| Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas MP Rethman, W Carpenter, EEW Cohen, J Epstein, CA Evans, CM Flaitz, ... The Journal of the American Dental Association 141 (5), 509-520, 2010 | 412 | 2010 |
| Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes MK Keck, Z Zuo, A Khattri, TP Stricker, CD Brown, M Imanguli, D Rieke, ... Clinical cancer research 21 (4), 870-881, 2015 | 376 | 2015 |
| Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease JK Salama, MD Hasselle, SJ Chmura, R Malik, N Mehta, KM Yenice, ... Cancer 118 (11), 2962-2970, 2012 | 354 | 2012 |
| Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label … MS Brose, ME Cabanillas, EEW Cohen, LJ Wirth, T Riehl, H Yue, ... The lancet oncology 17 (9), 1272-1282, 2016 | 353 | 2016 |
| Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma AG Sacco, EE Cohen Journal of clinical oncology 33 (29), 3305-3313, 2015 | 351 | 2015 |
| Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised … NY Lee, RL Ferris, A Psyrri, RI Haddad, M Tahara, J Bourhis, K Harrington, ... The Lancet Oncology 22 (4), 450-462, 2021 | 346 | 2021 |
